Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 5/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | HTR7 | P34969 | 3/20 | 0.38 |
| ▸ | HTR6 | P50406 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.36 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4341198 | 0.91 | OPRM1 (0.43) | SIGMAR1DRD2HTR1AHTR6MEN1 | |
| SCHEMBL4319927 | 0.89 | LMNA (0.43) | KCNH2SIGMAR1ATMMEN1KMT2A | |
| SCHEMBL4319914 | 0.88 | PPARG (0.36) | KCNH2DRD2OPRM1OPRK1 | |
| SCHEMBL4334582 | 0.86 | KCNH2 (0.40) | KCNH2SIGMAR1DRD2HTR1ASLC6A4 | |
| SCHEMBL4341403 | 0.79 | OPRM1 (0.41) | SIGMAR1DRD2HTR1AHTR6OPRM1 | |
| SCHEMBL4329500 | 0.79 | L3MBTL1 (0.39) | KCNH2DRD2HTR1ASLC6A4HTR7 | |
| SCHEMBL4327017 | 0.78 | ALDH1A1 (0.48) | HTR1AMEN1KMT2ANPSR1 | |
| SCHEMBL13913823 | 0.78 | HCRTR1 (0.38) | SIGMAR1DRD2HTR1A | |
| SCHEMBL8255127 | 0.78 | PPARG (0.31) | HTR6OPRM1OPRK1 | |
| SCHEMBL4333393 | 0.77 | HTR1A (0.41) | KCNH2DRD2HTR1ASLC6A4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | KCNH2 610/4885SIGMAR1 247/4885DRD2 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.